129 related articles for article (PubMed ID: 2223137)
1. The theoretical implications and experimental and clinical results of radiolabeled antiferritin.
Order SE
Acta Oncol; 1990; 29(6):689-94. PubMed ID: 2223137
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
[TBL] [Abstract][Full Text] [Related]
4. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
Order SE; Stillwagon GB; Klein JL; Leichner PK; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K; Finney K
J Clin Oncol; 1985 Dec; 3(12):1573-82. PubMed ID: 2415692
[TBL] [Abstract][Full Text] [Related]
5. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study.
Order S; Pajak T; Leibel S; Asbell S; Leichner P; Ettinger D; Stillwagon G; Herpst J; Haulk T; Kopher K
Int J Radiat Oncol Biol Phys; 1991 May; 20(5):953-63. PubMed ID: 1850722
[TBL] [Abstract][Full Text] [Related]
6. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.
Herpst JM; Klein JL; Leichner PK; Quadri SM; Vriesendorp HM
J Clin Oncol; 1995 Sep; 13(9):2394-400. PubMed ID: 7666099
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease.
Vriesendorp HM; Quadri SM
Cancer Biother Radiopharm; 2000 Oct; 15(5):431-45. PubMed ID: 11155816
[TBL] [Abstract][Full Text] [Related]
8. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.
Vriesendorp HM; Morton JD; Quadri SM
Cancer Res; 1995 Dec; 55(23 Suppl):5888s-5892s. PubMed ID: 7493365
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma.
Leichner PK; Yang NC; Frenkel TL; Loudenslager DM; Hawkins WG; Klein JL; Order SE
Int J Radiat Oncol Biol Phys; 1988 May; 14(5):1033-42. PubMed ID: 2834309
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration.
Vriesendorp HM; Quadri SM; Andersson BS; Wyllie CT; Dicke KA
Cancer; 1997 Dec; 80(12 Suppl):2721-7. PubMed ID: 9406730
[TBL] [Abstract][Full Text] [Related]
11. 90Yttrium antiferritin--a new therapeutic radiolabeled antibody.
Order SE; Klein JL; Leichner PK; Frincke J; Lollo C; Carlo DJ
Int J Radiat Oncol Biol Phys; 1986 Feb; 12(2):277-81. PubMed ID: 3005201
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
[TBL] [Abstract][Full Text] [Related]
13. Variables affecting the tumor localization of 131I-antiferritin in experimental hepatoma.
Rostock RA; Klein JL; Kopher KA; Order SE
Am J Clin Oncol; 1984 Feb; 7(1):9-18. PubMed ID: 6695855
[TBL] [Abstract][Full Text] [Related]
14. Selective tumor localization in experimental hepatoma by radiolabeled antiferritin antibody.
Rostock RA; Klein JL; Leichner P; Kopher KA; Order SE
Int J Radiat Oncol Biol Phys; 1983 Sep; 9(9):1345-50. PubMed ID: 6885547
[TBL] [Abstract][Full Text] [Related]
15. Antiferritin IgG antibody for isotopic cancer therapy.
Order SE; Klein JL; Leichner PK
Oncology; 1981; 38(3):154-60. PubMed ID: 6259569
[TBL] [Abstract][Full Text] [Related]
16. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
Hellman S
J Clin Oncol; 1985 Dec; 3(12):1569. PubMed ID: 2999345
[No Abstract] [Full Text] [Related]
17. Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody.
Saiful Alam AF
Br J Cancer; 1991 Apr; 63(4):503-7. PubMed ID: 2021533
[TBL] [Abstract][Full Text] [Related]
18. [131I antiferritin in the treatment of hepatoma and Hodgkin's disease].
Cohen Y; Moroz H
Harefuah; 1986 Dec; 111(11):398-9. PubMed ID: 3028919
[No Abstract] [Full Text] [Related]
19. Selection of reagents for human radioimmunotherapy.
Vriesendorp HM; Quadri SM; Stinson RL; Onyekwere OC; Shao Y; Klein JL; Leichner PK; Williams JR
Int J Radiat Oncol Biol Phys; 1992; 22(1):37-45. PubMed ID: 1727128
[TBL] [Abstract][Full Text] [Related]
20. Distribution of and physiologic factors that affect 131I-antiferritin tumor localization in experimental hepatoma.
Rostock RA; Klein JL; Leichner PK; Order SE
Int J Radiat Oncol Biol Phys; 1984 Jul; 10(7):1135-41. PubMed ID: 6746354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
